Lipid-lowering therapy use and achievement of cholesterol targets in an Australian diabetes clinic.
We documented temporal changes in the use of lipid-lowering medications and achievement of cholesterol targets in an Australian diabetes clinic. The number of patients using lipid-lowering therapy for primary or secondary cardiovascular prevention increased from 6 to 69% between 1993-1995 and 2014-2016, which corresponded to a decrease in low-density lipoprotein cholesterol levels from 3.7 to 2.4 mmol/L (P < 0.01).
['Kiburg|Katerina V|KV|0000-0002-3894-5793', 'Ward|Glenn M|GM|', "O'Neal|David N|DN|", 'MacIsaac|Richard J|RJ|']
D000328:Adult D000368:Aged D000369:Aged, 80 and over D000924:Anticholesteremic Agents D002318:Cardiovascular Diseases D008078:Cholesterol, LDL D003920:Diabetes Mellitus D005260:Female D006801:Humans D006937:Hypercholesterolemia D008297:Male D008875:Middle Aged D011322:Primary Prevention D055502:Secondary Prevention D014739:Victoria
lipid-lowering therapy cholesterol diabetes cardiovascular disease endocrinology